KINIKSA PHARMACEUTICALS, LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.87 USD | -0.06% |
|
-2.43% | -3.82% |
| Apr. 03 | Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating | MT |
| Apr. 02 | Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Kiniksa Pharm...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.88
USD
Average target price
28.2
USD
Spread / Average Target
+67.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.82% | 1.19B | |
| -2.50% | 102B | |
| +2.49% | 96.07B | |
| -1.22% | 21.66B | |
| -17.20% | 20.77B | |
| -7.01% | 18.53B | |
| -40.31% | 16.91B | |
| -27.85% | 13.79B | |
| +0.25% | 13.33B | |
| +20.54% | 10.94B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Transcript : Kiniksa Pharmaceuticals, Ltd., Q2 2022 Earnings Call, Aug 03, 2022
